Other p53 structure correctors which reached the clinical trials’ testing include COTI-2 [87] or PC14586, a small molecule p53 reactivator that is selective for the p53 Y220C mutation [104], yet these drugs are not being evaluated in MDS or AML patients and therefore will not be discussed in detail in this review. Here, TP53 is linked to myelodysplastic syndrome.